On October 2, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that four abstracts highlighting its TIL therapy will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland (Press release, Iovance Biotherapeutics, OCT 2, 2019, View Source [SID1234540022]). One of the abstracts is a late-breaking submission and presentation details will be made available to the public on November 1, 2019. Details on the three posters that will be presented as part of the regular submissions are below.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process
Author: Abelson et al.
Poster #: P145
Presentation date/time: November 8, 2019, 7:00 am – 8:00 pm
Title: Silencing PD-1 using self-delivering RNAi PH-762 to improve Iovance TIL effector function using Gen 2 manufacturing method
Author: Azoulay-Alfaguter et al.
Poster #: P149
Presentation date/time: November 8, 2019, 7:00 am – 8:00 pm
Title: Iovance Gen2 TIL manufacturing process produces drug products that exhibit favorable quality attributes for adoptive cell transfer across 5 solid tumor indications
Author: Wardell et al.
Poster #: P226
Presentation date/time: November 9, 2019, 7:00 am – 8:30 pm
The SITC (Free SITC Whitepaper) abstract titles are listed on the conference website under Abstracts at View Source